CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 70 enrolled
Drug / intervention
topotecandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00267488
NCT00267488Phase 2Completed
CompareCT.gov

An Open-label, Phase II, Multicenter Study of Intravenous Weekly Topotecan in Subjects With Recurrent or Persistent Endometrial Cancer

GlaxoSmithKline·interventional·Posted Dec 21, 2005·Updated Jul 11, 2012

In Brief

A Phase 2 clinical trial evaluating topotecan for Neoplasms, Endometrial and Endometrial Cancer. Completed, enrolled 70 participants across 24 sites in 3 countries.

Detailed Summary

The purpose of this study is to find out if Hycamtin given weekly is safe and effective for treating your endometrial cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms, Endometrial, Endometrial Cancer
CountriesCanada, Hungary, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 21, 2005
Enrollment StartOct 1, 2005
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 20.5 years ago

Interventions

topotecandrug